Oruka Therapeutics and Orchid Island Capital report stock declines

Oruka Therapeutics (NASDAQ: ORKA) saw its stock price decline by 4.3% during mid-day trading, reaching a low of $81.90. The company recently reported an earnings per share (EPS) of ($0.55), missing the consensus estimate of ($0.51). While some analysts maintain buy ratings with price targets as high as $200.00, others have recently lowered their ratings.

Orchid Island Capital (NYSE: ORC), a real estate investment trust, recently hit a 52-week low, trading as low as $4.99. The company's previous quarterly report showed revenue of $59.97 million, which was below analyst estimates of $74.26 million, and an EPS of $0.26 against an expected $0.28. Orchid Island Capital has scheduled its third-quarter 2026 results release for October 22, 2026, with an earnings conference call to follow on October 23, 2026.